增加的心脏上腺激素驱动在人类心力衰竭中普遍同情激活之前
B Rundqvist1, M Elam, Y Bergmann-Sverrisdottir
1Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden. bengtr@wlab.wall.gu.se
Circulation
|January 7, 1997
概括
早期的充血性心力衰竭 (CHF) 显示了心脏北上腺素 (NE) 溢出增加,表明心脏上腺素驱动力增加. 这发生在在晚期心血管衰竭中看到的广泛的交感神经系统激活之前.
科学领域:
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
- 身体生理学 身体生理学
背景情况:
- 之前的研究表明,在重症结血性心力衰竭 (CHF) 中,心脏和脏的诺亚上腺素 (NE) 溢出增加.
- 有限的数据存在于区域交感神经系统活动在早期的CHF.
- 这项研究调查了心脏,脏和骨肌肉在CHF严重程度的同情功能.
研究的目的:
- 评估区域交感神经系统活动在轻度至中度和严重的心脏病发作.
- 为了比较CHF患者与健康对照者的同情性概况.
- 为了确定心脏上腺激素驱动是否在早期心脏不全症中发生变化.
主要方法:
- 使用同位素稀释 [3H]NE输注来评估心脏和脏的NE溢出.
- 通过内部神经记录测量了对骨肌肉血管床 (MSA) 的交感神经流量.
- 在健康受试者,轻度至中度心血管疾病和严重心血管疾病组中比较NE溢出和MSA.
主要成果:
- 与对照组相比,心脏NE溢出在轻度至中度 (3倍) 和严重 (4倍) CHF中显著增加.
- 总体和脏NE溢出,以及MSA,在轻度至中度的CHF中没有差异,但在严重的CHF中升高.
- 通过心脏 [3H]NE 的微分提取在两组CHF中减少了~40%.
结论:
- 轻度至中度的CHF表现出心脏上腺激素驱动的选择性增加.
- 这种加剧的心脏交感活性先于在晚期CHF中观察到的通用交感激活.
- 这些发现表明,交感神经系统参与CHF进展的独特模式.
相关概念视频
01:16Sympathetic Activation
The sympathetic division can influence tissues and organs by releasing norepinephrine at peripheral synapses and distributing epinephrine and norepinephrine through the bloodstream. In times of crisis or stress, sympathetic activation occurs, which is regulated by sympathetic centers in the hypothalamus. As a result, sympathetic activation prepares the body for physical exertion, rapid ATP production, and heightened alertness, allowing individuals to respond effectively to challenging or...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...